학술논문
93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Document Type
Abstract
Author
Source
In Annals of Oncology May 2021 32 Supplement 2:S62-S62
Subject
Language
ISSN
0923-7534